Pharmacotherapeutic approaches to the treatment of Alzheimer's disease

Clinical Therapeutics
John B Standridge

Abstract

Alzheimer's disease (AD), a progressive degenerative disorder of the brain, is the most common cause of cognitive impairment in the elderly. The pharmacotherapy of AD is evolving rapidly. Cholinergic stabilization with cholinesterase-inhibitor (ChEI) therapy implies neuroprotection and a resultant slowing of disability and disease progression. The moderate-affinity N-methyl-d-aspartate (NMDA)-receptor antagonist memantine may block neural excitotoxicity. The purpose of this review was to examine the evidence for the responsiveness to pharmacotherapy of established AD; specifically, the extent to which the benefits of therapy have been proved, the extent to which currently available ChEIs support cholinergic neurotransmission, and the extent to which currently available ChEIs and memantine provide neuroprotection. Relevant studies were identified through a comprehensive search of MEDLINE for articles published between January 1999 and February 2004 using the terms Alzheimer's pharmacotherapy, cholinesterase inhibitor therapy, Alzheimer's disease, donepezil, rivastigmine, galantamine, glutamatergic system modifiers, and memantine; a search of the reference lists of identified articles; and a manual search of pertinent journals. A...Continue Reading

References

Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·J T GreenamyreA B Young
Nov 29, 2002·Dementia and Geriatric Cognitive Disorders·Anders WimoUNKNOWN Donepezil Nordic Study Group
Dec 10, 2002·Neurobiology of Aging·Martin Citron
Feb 5, 2003·Dementia and Geriatric Cognitive Disorders·Rafael BlesaSusanne Schwalen
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Mary L Michaelis
Mar 6, 2003·Journal of Clinical Pharmacology·Qinying ZhaoJean-Loup Parier
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Marek SamochockiAlfred Maelicke
Mar 26, 2003·Neurology·Norio OhkoshiShin'ichi Shoji
Apr 24, 2003·American Journal of Alzheimer's Disease and Other Dementias·Sharon A Brangman
May 8, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yuki TakadaAkinori Akaike
Jun 28, 2003·CNS Drugs·D Allan Butterfield, Chava B Pocernich
Jul 2, 2003·Journal of the American Geriatrics Society·David S GeldmacherJohn R Ieni
Jul 24, 2003·Drugs & Aging·Gordon WilcockUNKNOWN GAL-GBR-2 Study Group
Sep 18, 2003·Journal of Neuroscience Research·Neelima B Chauhan, George J Siegel
Oct 9, 2003·International Journal of Geriatric Psychiatry·Mary SanoShane Kavanagh
Nov 14, 2003·The New England Journal of Medicine·Richard SchulzUNKNOWN Resources for Enhancing Alzheimer's Caregiver Health Investigators
Jan 21, 2004·The International Journal of Neuropsychopharmacology·T MatsumotoK Kosaka
Jan 31, 2004·European Journal of Pharmacology·Dane R ListonW Frost White

❮ Previous
Next ❯

Citations

Nov 30, 2010·Bulletin of Experimental Biology and Medicine·N A KapaiV G Skrebitskii
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Abraham Fisher
Jun 4, 2008·Optometry and Vision Science : Official Publication of the American Academy of Optometry·William CheungM Francesca Cordeiro
Sep 7, 2007·Alzheimer Disease and Associated Disorders·Carol E FranzLadson Hinton
Mar 21, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·A D Hutchinson, J L Mathias
Apr 2, 2005·Dementia and Geriatric Cognitive Disorders·Koene R A van DijkErik J A Scherder
Jun 21, 2011·Qualitative Health Research·Ester Carolina Apesoa-VaranoLadson Hinton
Dec 14, 2006·Clinical Drug Investigation·T Heinen-KammererR Rychlik
Sep 22, 2007·Radiology·Dima A HammoudMartin G Pomper
Mar 13, 2014·International Clinical Psychopharmacology·Heidi TaipaleSirpa Hartikainen
Jan 15, 2011·Drug Development and Industrial Pharmacy·N Başaran MutluAhmet Nacar
Mar 27, 2009·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Perla Werner
Feb 19, 2015·Therapeutic Delivery·Xiao GuXiaoling Gao
May 11, 2013·General Hospital Psychiatry·Anne M DohertyJohn Cooney
May 23, 2014·Journal of Medicinal Chemistry·Bellinda BenhamúMaría L López-Rodríguez
Feb 28, 2006·Journal of the American Medical Directors Association·John B Standridge
Oct 21, 2006·Lancet Neurology·Silvia SörensenMartin Pinquart
Jan 27, 2007·Journal of Enzyme Inhibition and Medicinal Chemistry· Atta-ur-RahmanM Iqbal Choudhary
Jan 9, 2010·Biochimica Et Biophysica Acta·Tsu Tshen Chuang
Jul 15, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tomáš SiatkaJakub Chlebek
Mar 4, 2009·Critical Reviews in Clinical Laboratory Sciences·Jordi CampsJorge Joven
Jan 5, 2012·Psychiatry Investigation·Nina KhachiyantsKye Y Kim
Oct 13, 2019·Current Pharmaceutical Design·Md Tanvir KabirGhulam Md Ashraf
Apr 25, 2015·Angewandte Chemie·Peter SchröderHerbert Waldmann
Aug 27, 2019·Frontiers in Aging Neuroscience·Yingni SunHongwei Gao
Oct 11, 2005·The Journal of Pharmacology and Experimental Therapeutics·C M HernandezA V Terry
Oct 19, 2011·Archiv der Pharmazie·Mehlika Dilek AltintopGülşen Akalın
Oct 11, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Miro JakovljevicRadmila Topic
Jan 14, 2020·Nanomedicine : Nanotechnology, Biology, and Medicine·Hossein DerakhshankhahJohn F Presley
Nov 28, 2006·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Elena I SolntsevaVladimir G Skrebitsky
Feb 15, 2011·Pharmacology, Biochemistry, and Behavior·Alvin V TerryScott J Webster

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.